Results 111 to 120 of about 101,286 (277)
International Journal of Cancer, EarlyView.What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source
Radiation induced lichen planus - an uncommon side effect [PDF]
, 2019 Cutaneous lichen planus is classically characterized by violaceous, pruritic, planar papules and plaques, most commonly affecting the extremities. Lichen planus following radiation therapy is extremely rare and lichen planus following radiation therapy ...
Chen, Yi-Chun +4 more
core
International Journal of Cancer, EarlyView.Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval +8 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti +4 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken +20 more
wiley +1 more source
iNew Medicine, EarlyView.ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu +4 more
wiley +1 more source
Interdisciplinary Medicine, EarlyView.Napabucasin reduces liver metastases by reprogramming the hepatic microenvironment. It induces hepatocyte secretion of CCL21 via c‐Fos activation, recruiting lymphocytes and converting “cold” metastases into immunologically “hot” tumors. This effect is liver‐specific and independent of cancer cells.
Qiongqiong Wang +19 more
wiley +1 more source
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]
, 2019 The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is an increasing option for axillary surgery in patients responding to treatment, whether diagnosed as clinically node‐negative (cN0) or node‐positive (cN + ). This study evaluates SLNB trends in patients with NAT in a large European population.
Antonio J. Esgueva +49 more
wiley +1 more source
Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review
JEADV Clinical Practice, EarlyView.ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga +6 more
wiley +1 more source